Erectile Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Erectile Dysfunction Pipeline Drugs Market Overview
Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use, and medications, including antidepressants, antihistamines, and medications to treat high blood pressure, pain, or prostate cancer.
The Erectile Dysfunction drugs in development market research report provide comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects.
Key Targets in the Erectile Dysfunction Pipeline Products Market
The key targets in the Erectile Dysfunction pipeline products market are Phosphodiesterase 5, Sodium Dependent Dopamine Transporter, D1A Dopamine Receptor, D2 Dopamine Receptor, Sodium Dependent Serotonin Transporter, 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 2C, Adenosine Receptor A3, Angiopoietin 1 Receptor, Beta 3 Adrenergic Receptor, and others.
Erectile Dysfunction Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Erectile Dysfunction Pipeline Products Market
The key mechanisms of action in the Erectile Dysfunction pipeline products market are Phosphodiesterase 5 Inhibitor, Sodium Dependent Dopamine Transporter Inhibitor, D1A Dopamine Receptor Agonist, D2 Dopamine Receptor Agonist, Sodium Dependent Serotonin Transporter Inhibitor, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, Adenosine Receptor A3 Agonist, Angiopoietin 1 Receptor Agonist, Beta 3 Adrenergic Receptor Agonist, and others.
Erectile Dysfunction Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Erectile Dysfunction Pipeline Products Market
The key routes of administration in the Erectile Dysfunction pipeline products market are oral, topical, sublingual, intracavernous, intramuscular, nasal, parenteral, buccal, inhalational, intracardiac, and others.
Erectile Dysfunction Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Erectile Dysfunction Pipeline Products Market
The key molecule types in the Erectile Dysfunction pipeline products market are small molecule, cell therapy, biologic, fusion protein, recombinant protein, antisense RNAi oligonucleotide, gene therapy, and RNAi gene therapy.
Erectile Dysfunction Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Erectile Dysfunction Pipeline Products Market
Some of the major companies in the Erectile Dysfunction pipeline products market are Chengdu Dikang Pharmaceuticals Co Ltd, Initiator Pharma AS, NAL Pharmaceuticals Ltd, AnyGen Co Ltd, Aprogen Inc, Aquestive Therapeutics Inc, Arovella Therapeutics Ltd, Astellas Pharma Inc, Autotelic Bio Inct, and Benuvia Therapeutics Inc.
Erectile Dysfunction Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
Key targets | Phosphodiesterase 5, Sodium Dependent Dopamine Transporter, D1A Dopamine Receptor, D2 Dopamine Receptor, Sodium Dependent Serotonin Transporter, 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 2C, Adenosine Receptor A3, Angiopoietin 1 Receptor, Beta 3 Adrenergic Receptor, and others |
Key mechanism of action | Phosphodiesterase 5 Inhibitor, Sodium Dependent Dopamine Transporter Inhibitor, D1A Dopamine Receptor Agonist, D2 Dopamine Receptor Agonist, Sodium Dependent Serotonin Transporter Inhibitor, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, Adenosine Receptor A3 Agonist, Angiopoietin 1 Receptor Agonist, Beta 3 Adrenergic Receptor Agonist, and others |
Key routes of administration | Oral, Topical, Sublingual, Intracavernous, Intramuscular, Nasal, Parenteral, Buccal, Inhalational, Intracardiac, and Others |
Key molecule type | Small Molecule, Cell Therapy, Biologic, Fusion Protein, Recombinant Protein, Antisense RNAi Oligonucleotide, Gene Therapy, and RNAi Gene Therapy |
Major companies | Chengdu Dikang Pharmaceuticals Co Ltd, Initiator Pharma AS, NAL Pharmaceuticals Ltd, AnyGen Co Ltd, Aprogen Inc, Aquestive Therapeutics Inc, Arovella Therapeutics Ltd, Astellas Pharma Inc, Autotelic Bio Inct, and Benuvia Therapeutics Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
- The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Aprogen Inc
Aquestive Therapeutics Inc
Arovella Therapeutics Ltd
Astellas Pharma Inc
Autotelic Bio Inc
Benuvia Therapeutics Inc
Biozeus Pharmaceutical SA
Can-Fite BioPharma Ltd
Chengdu Dikang Pharmaceuticals Co Ltd
Cure Pharmaceutical Holding Corp
Dicot AB
Evincis Bio Inc
Exopharm Ltd
Fabre-Kramer Pharmaceuticals Inc
Farmalider SA
Guangzhou Four-Leaf Clover HealthTech Co Ltd
Hemostemix Inc
Humanetics Corp
ILGEN Inc
Initiator Pharma AS
IntelGenx Corp
Jiangsu Hengrui Medicine Co Ltd
Klaria Pharma Holding AB
Lexaria Bioscience Corp
MannKind Corp
Mezzion Pharma Co Ltd
MicroCures Inc
Mitsubishi Tanabe Pharma Corp
MyX Therapeutics Inc
NAL Pharmaceuticals Ltd
Organicell Regenerative Medicine Inc
Orgenesis Inc
PeLeMed Co Ltd
Pharmicell Co Ltd
Reven Holdings Inc
S1 Biopharma Inc
Seelos Therapeutics, Inc.
Shandong Lukang Pharmaceutical Co Ltd
siRNAgen Therapeutics Corp
Targazyme Inc
Tavanta Therapeutics Inc
Techfields Pharma Co Ltd
Tritech Biopharmaceuticals Co Ltd
Venturis Therapeutics Inc
XuanZhu Biological Technology Co Ltd
Yangtze River Pharmaceutical Group
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Erectile Dysfunction pipeline products market?
The key targets in the Erectile Dysfunction pipeline products market are Phosphodiesterase 5, Sodium Dependent Dopamine Transporter, D1A Dopamine Receptor, D2 Dopamine Receptor, Sodium Dependent Serotonin Transporter, 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 2C, Adenosine Receptor A3, Angiopoietin 1 Receptor, Beta 3 Adrenergic Receptor, and others.
-
What are the key mechanisms of action in the Erectile Dysfunction pipeline products market?
The key mechanisms of action in the Erectile Dysfunction pipeline products market are Phosphodiesterase 5 Inhibitor, Sodium Dependent Dopamine Transporter Inhibitor, D1A Dopamine Receptor Agonist, D2 Dopamine Receptor Agonist, Sodium Dependent Serotonin Transporter Inhibitor, 5-Hydroxytryptamine Receptor 2A Antagonist, 5-Hydroxytryptamine Receptor 2C Antagonist, Adenosine Receptor A3 Agonist, Angiopoietin 1 Receptor Agonist, Beta 3 Adrenergic Receptor Agonist, and others.
-
What are the key routes of administration in the Erectile Dysfunction pipeline products market?
The key routes of administration in the Erectile Dysfunction pipeline products market are oral, topical, sublingual, intracavernous, intramuscular, nasal, parenteral, buccal, inhalational, intracardiac, and others.
-
What are the key molecule types in the Erectile Dysfunction pipeline products market?
The key molecule types in the Erectile Dysfunction pipeline products market are small molecule, cell therapy, biologic, fusion protein, recombinant protein, antisense RNAi oligonucleotide, gene therapy, and RNAi gene therapy.
-
Which are the major companies in the Erectile Dysfunction pipeline products market?
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.